FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPE	ROVAL
OMB Number:	3235-0287
Estimated average	burden
ha nar raananaa	. 0 5

longer subject to
Section 16. Form 4 or
Form 5 obligations
may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(1 IIII OI I y	pe response	3)															
Name and Address of Reporting Person * Loewy Caroline M			2. Issuer Name and Ticker or Trading Symbol Aptose Biosciences Inc. [APTO]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X_Director 10% Owner							
(Last) (First) (Middle) C/O APTOSE BIOSCIENCES, 251 CONSUMERS ROAD, SUITE 1105			3. Date of Earliest Transaction (Month/Day/Year) 01/31/2020							Officer (giv	e title below)	Other	(specify below)				
(Street) TORONTO, A6 M2J 4R3			4. If Amendment, Date Original Filed(Month/Day/Year)							_X_ F	6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting PersonForm filed by More than One Reporting Person						
(City	y)	(State)	(Zip)			Ta	ble I	- Non-Der	ivative S	Securitie	es Acquired,	red, Disposed of, or Beneficially Owned					
1.Title of S (Instr. 3)				2A. Deemed Execution Date, any (Month/Day/Ye		Date, if C	(Instr. 8)		4. Securities Acqu (A) or Disposed of (Instr. 3, 4 and 5)						ownership orm: Oirect (D) Or	. Nature f Indirect geneficial Ownership Instr. 4)	
							Coc	de V	Amount	(A) 01 (D)	Price			`	Instr. 4)		
			Table II -					displa	ys a cu oosed of,	rrently or Bene	equired to valid OMB eficially Owr ities)	control r		: 1011II			
1. Title of Derivative Security (Instr. 3)	Conversion	(Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. f Transaction Code		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Ex Expiration (Month/D	Exercisable and on Date		7. Title and of Underlyi Securities (Instr. 3 and	ng		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s	Ownership Form of Derivative Security: Direct (D) or Indirect	11. Nature of Indirec Beneficial Ownershi (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisab	Expir le Date	ation	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)		
Director Option Grant	\$ 6.91	01/31/2020		A		65,000		(1)	01/3	0/2030	Common Shares	65,000	\$ 0	65,000	D		

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Loewy Caroline M C/O APTOSE BIOSCIENCES 251 CONSUMERS ROAD, SUITE 1105 TORONTO, A6 M2J 4R3	X						

Signatures

/s/ Gregory K. Chow, as attorney-in-fact for Caroline M. Loewy	02/03/2020
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Fifty percent (50%) of the options vest on 1/31/2021. The remaining 50% vest as follows: one-half on 1/31/2022 and one-half on 1/31/2023.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.